---
title: "CSPC Pharmaceutical Group: Revenue and profit soared on finished drug sales and licensing, with strong R&D and global deals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296434166.md"
description: "Revenue surged 40.1% to RMB18.6 billion and profit attributable to shareholders jumped 139.2% year-over-year, driven by strong finished drug sales and a sharp rise in licence fee income. Strategic partnerships and robust R&D investment underpin future growth.Original document: CSPC Pharmaceutical Group Limited [1093] Earnings Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-20T04:22:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296434166.md)
  - [en](https://longbridge.com/en/news/296434166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296434166.md)
generator: "portal-rs"
---

# CSPC Pharmaceutical Group: Revenue and profit soared on finished drug sales and licensing, with strong R&D and global deals

Revenue surged 40.1% to RMB18.6 billion and profit attributable to shareholders jumped 139.2% year-over-year, driven by strong finished drug sales and a sharp rise in licence fee income. Strategic partnerships and robust R&D investment underpin future growth.

Original document: CSPC Pharmaceutical Group Limited \[1093\] Earnings Release — Aug. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [Indra says FaRADAI R&D validates explainable AI to assess threats, plot safe routes in military operations](https://longbridge.com/en/news/296213236.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**